ClinicalTrials.gg
CompletedNCT02942290Updated Aug 12, 2026

A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)

A Phase 1 interventional study of Azacitidine and Venetoclax in Myelodysplastic Syndromes (MDS), sponsored by AbbVie. Completed at 37 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
134
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 130 studies testing azacitidine in Myelodysplastic Syndromes — 13 open to participants now, 25 under way, 3 of them phase 3. Azacitidine · Myelodysplastic Syndromes.

Enrollment
16th of 126
134 · median 38
Started
2017
with 6 others
Phase 1
30 of 130
4 open now
Registered
87th of 130
by date
Lead sponsor
2 of 130
AbbVie

Among the 130 studies testing azacitidine in Myelodysplastic Syndromes, this one is the 16th largest by enrollment of the 126 interventional ones that give a count, is one of 7 that started in 2017, is one of 30 in phase 1, and was the 87th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

13 of the 130 studies testing azacitidine in Myelodysplastic Syndromes are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About azacitidine

Azacitidine: first FDA approval 2004 (VIDAZA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies testing azacitidine in Myelodysplastic Syndromes, or all of them as a file.
02

Study summary

This is a Phase 1b, open-label, non-randomized, multicenter, dose-finding study evaluating venetoclax in combination with azacitidine in participants with treatment-naïve higher-risk MDS comprising a dose-escalation portion and a safety expansion portion.

03

Conditions studied

  • Myelodysplastic Syndromes (MDS)

Keywords

  • Higher-Risk (HR) Myelodysplastic Syndromes (MDS)
  • Pharmacokinetic
  • Venetoclax
  • Azacitidine
  • Acute Myelogenous Leukemia
  • Myelodysplastic Syndromes (MDS)
  • Treatment-Naïve Higher-Risk
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must have documented diagnosis of untreated de novo MDS with:

    • International Prognostic Scoring System (IPSS) risk categories Int-2 or High (minimum IPSS overall score of 1.5) OR Revised IPSS (IPSS-R) categories intermediate, high or very high (score of > 3) and
    • Presence of less than 20% bone marrow blasts per bone marrow /aspirate.
  • (ECOG) performance score of less than or equal to 2.

Exclusion criteria

Exclusion Criteria:

  • Participant has received prior therapy for MDS. (Prior supportive care in form of transfusions or growth factors, etc., is not considered prior therapy).
  • Participant has received prior therapy with a BCL-2 Homology 3 (BH3) mimetic.
  • Participant has a diagnosis other than previously untreated de novo MDS (as defined in the protocol) including:

    • MDS with IPSS risk categories Low or Int-1 (overall IPSS score \< 1.5)
    • Therapy-related MDS (t-MDS).
    • MDS evolving from a pre-existing myeloproliferative neoplasm (MPN).
    • MDS/MPN including chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (CML), juvenile myelomonocytic leukemia (JMML) and unclassifiable MDS/MPN.
  • Participant has received Hematopoietic Stem Cell Transplantation (HSCT) or solid organ transplantation.
  • Participant has received a within 4 weeks prior to the first dose of study drug.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
134 participants (actual)

Study arms

  • Experimental
    Venetoclax + Azacitidine

    Drug: Azacitidine · Drug: Venetoclax

Interventions

  • Powder for injection; taken subcutaneously (SC) or intravenous (IV); Administered on Days 1-7 of 28 days cycle or Days 1-5 of Week 1 \& Days 1-2 of Week 2 of 28 day cycle.

  • Oral; Tablet

    Also known as: ABT-199, GDC-0199, VENCLEXTA

06

What researchers measure

Primary outcomes

  1. AUCt for Azacitidine

    Area under the plasma concentration-time curve (AUC) from 0 to the time of the last measurable concentration (AUCt) for azacitidine.

    Time frame: Up to 32 days

  2. Cmax of venetoclax

    Maximum plasma concentration (Cmax) of venetoclax.

    Time frame: Up to 32 days

  3. AUCt for venetoclax

    Area under the plasma concentration-time curve (AUC) from 0 to the time of the last measurable concentration (AUCt) for venetoclax.

    Time frame: Up to 32 days

  4. Tmax of venetoclax

    Time to Cmax (peak time, Tmax) of venetoclax.

    Time frame: Up to 32 days

  5. AUC[0 to infinity] for azacitidine

    Area under the plasma concentration-time curve from Time 0 to infinite time.

    Time frame: Up to 32 days

  6. Recommended Phase 2 dose (RPTD) and dosing schedule of venetoclax in combination with azacitidine

    The RPTD of venetoclax \[co-administered venetoclax and azacitidine\] will be determined during the dose escalation phase of the study. RPTD will be determined using available safety and pharmacokinetics data \[upon completion of the dose escalation phase\].

    Time frame: Measured from Day 1 until Day 28 per dose level.

  7. Half-life (t[1/2]) for azacitidine

    Terminal elimination half-life (t\[1/2\]) for azacitidine.

    Time frame: Up to 32 days

  8. Cmax for azacitidine

    Maximum plasma concentration (Cmax) of azacitidine.

    Time frame: Up to 32 days

  9. AUC[0-24] for venetoclax

    AUC over a 24-hour dose interval (AUC\[0-24\]) for venetoclax.

    Time frame: Up to 32 days

  10. Clearance (CL) for azacitidine

    Clearance is defined as the volume of plasma cleared of the drug per unit time.

    Time frame: Up to 32 days

  11. Tmax for azacitidine

    Time to Cmax (peak time, Tmax) of azacitidine.

    Time frame: Up to 32 days

  12. Complete Remission (CR) Rate

    Complete remission rate will be defined as the proportion of participants who achieved a complete response per the International Working Group (IWG) 2006 criteria for Myelodysplastic Syndromes (MDS).

    Time frame: Measured from Cycle 1 Day 1 as long as the participant continues to benefit, or until the occurrence of unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent, and for an anticipated maximum duration of 24 months.

Secondary outcomes

  1. Rate of red blood cell (RBC) transfusion independence

    Percentages of participants who become RBC transfusion-independent.

    Time frame: Measured from Cycle 1 Day 1 as long as the participant continues to benefit, or until the occurrence of unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent, and for an anticipated maximum duration of 24 months.

  2. Progression-Free Survival (PFS)

    PFS is defined as the number of days from the date of the first dose of study drug to the date of earliest disease progression or death due to disease progression or febrile neutropenia.

    Time frame: Measured from the date of first dose of study drug to the date of earliest disease progression or death due to disease progression or febrile neutropenia, and for an anticipated maximum duration of 24 months.

  3. Overall Survival (OS)

    OS is defined as number of days from the date of first dose of the study drug to the date of death of any cause.

    Time frame: Measured from the date of first dose of study drug to the date of death, and for up to 5 years after the last participant is enrolled.

  4. Hematologic Improvement (HI) rate

    Percentages of participants with HI (erythroid/platelet/neutrophil responses).

    Time frame: Measured from Cycle 1 Day 1 as long as the participant continues to benefit, or until the occurrence of unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent, and for an anticipated maximum duration of 24 months.

  5. Rate of platelet (PLT) transfusion independence

    Percentages of participants who become platelet transfusion-independent.

    Time frame: Measured from Cycle 1 Day 1 as long as the participant continues to benefit, or until the occurrence of unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent, and for an anticipated maximum duration of 24 months.

  6. Event-Free Survival (EFS)

    Event-free survival (EFS) will be defined as the number of days from the date of the first dose of study drug to the date of earliest disease progression or death of any cause.

    Time frame: Measured from the date of the first dose of study drug to the date of earliest disease progression, death of any cause and for up to 5 yrs after the last participant is enrolled

  7. Time to transformation to acute myeloid leukemia (AML)

    Defined as the number of days from the date of the first dose of study drug to the date of documented AML transformation.

    Time frame: Measured from the date of first dose of study drug to date of documented AML transformation, defined as the presence of blast count greater than or equal to 20% in either peripheral blood or bone marrow for an anticipated maximum duration of 24 months.

  8. Overall Response Rate (OR)

    OR (equals the rates of complete remission \[CR\] + partial remission \[PR\]) of venetoclax in combination with azacitidine.

    Time frame: Measured from Cycle 1 Day 1 as long as the participant continues to benefit, or until the occurrence of unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent and for an anticipated maximum duration of 24 months.

  9. Time to next treatment (TTNT)

    Time to next treatment (TTNT) will be defined as the time from the first dose of study drug to start of new non-protocol specified MDS therapy or death from any cause.

    Time frame: Measured from the first dose of study drug to start of new non-protocol specified MDS therapy, and for up to 5 years after the last participant is enrolled.

  10. Marrow Complete Remission (mCR) Rate

    Defined as the proportion of participants who achieved a marrow complete response with or without hematological improvement per the International Working Group (IWG) 2006 criteria for Myelodysplastic Syndromes.

    Time frame: Measured from Cycle 1 Day 1 as long as the participant continues to benefit, or until the occurrence of unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent, and for an anticipated maximum duration of 24 months.

  11. Modified Overall Response Rate (mOR)

    mOR (equals CR + PR + mCR) of venetoclax in combination with azacitidine.

    Time frame: Measured from Cycle 1 Day 1 as long as the participant continues to benefit, or until the occurrence of unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent and for an anticipated maximum duration of 24 months.

  12. Duration of CR

    Duration of CR will be defined as the number of days from the date of first response CR to the earliest documentation of progressive disease or death of any cause, whichever occurs earlier.

    Time frame: Measured from Cycle 1 Day 1 as long as the participant continues to benefit, or until the occurrence of unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent, and for an anticipated maximum duration of 24 months.

  13. Duration of mOR

    Duration of response (mOR) will be defined as the number of days from the date of first response (CR, PR or mCR) to the earliest documentation of progressive disease or death of any cause, whichever occurs earlier.

    Time frame: Measured from Cycle 1 Day 1 as long as the participant continues to benefit, or until the occurrence of unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent and for an anticipated maximum duration of 24 months.

  14. Duration of OR

    Duration of response (OR) will be defined as the number of days from the date of first response (CR or PR) to the earliest documentation of progressive disease or death of any cause, whichever occurs earlier.

    Time frame: Measured from Cycle 1 Day 1 as long as the participant continues to benefit, or until the occurrence of unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent and for an anticipated maximum duration of 24 months.

  15. Rate of AML transformation

    The AML transformation rate is defined as the proportion of participants transformed to Acute Myelogenous Leukemia.

    Time frame: Measured from the date of first dose of study drug to date of documented AML transformation, defined as the presence of blast count greater than or equal to 20% in either peripheral blood or bone marrow for an anticipated maximum duration of 24 months.

  16. Time to First Response (CR)

    Time to first response (CR) will be defined as the number of days from the date of first dose of the study drug to the date of the first response of CR.

    Time frame: Measured from Cycle 1 Day 1 as long as the participant continues to benefit, or until the occurrence of unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent, and for an anticipated maximum duration of 24 months.

  17. Time to First Response (mOR)

    Time to first response (mOR) will be defined as the number of days from the date of first dose of the study drug to the date of the first response of (CR, PR, or mCR).

    Time frame: Measured from Cycle 1 Day 1 as long as the participant continues to benefit, or until the occurrence of unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent and for an anticipated maximum duration of 24 months.

  18. Time to First Response (OR)

    Time to first response (OR) will be defined as the number of days from the date of first dose of the study drug to the date of the first response of (CR or PR).

    Time frame: Measured from Cycle 1 Day 1 as long as the participant continues to benefit, or until the occurrence of unacceptable toxicity, death, exercise of investigator discretion, or withdrawal of consent and for an anticipated maximum duration of 24 months.

07

Study locations

37 sites
  • Duplicate_University of Arizona Cancer Center - North Campus /ID# 154155
    Tucson, Arizona 85719-1478, United States
  • The University of Chicago Medical Center /ID# 153673
    Chicago, Illinois 60637-1443, United States
  • University of Maryland, Baltimore /ID# 153669
    Baltimore, Maryland 21201, United States
  • Tufts Medical Center /ID# 153672
    Boston, Massachusetts 02111-1552, United States
  • Dana-Farber Cancer Institute /ID# 152735
    Boston, Massachusetts 02215, United States
  • Washington University-School of Medicine /ID# 153671
    St Louis, Missouri 63110, United States
  • Columbia University Medical Center /ID# 153661
    New York, New York 10032-3729, United States
  • Weill Cornell Medical College /ID# 155524
    New York, New York 10065, United States
  • Oregon Medical Research Center /ID# 152734
    Portland, Oregon 97239, United States
  • University of Pittsburgh MC /ID# 153662
    Pittsburgh, Pennsylvania 15260, United States
  • Tennessee Oncology-Nashville Centennial /ID# 222769
    Nashville, Tennessee 37203-1632, United States
  • Vanderbilt University Medical Center /ID# 152738
    Nashville, Tennessee 37232-0011, United States
  • UT MD Anderson Cancer Center /ID# 153809
    Houston, Texas 77030, United States
  • Concord Repatriation General Hospital /ID# 154958
    Concord, New South Wales 2139, Australia
  • Duplicate_St. Vincent's Hospital, Darlinghurst /ID# 222846
    Darlinghurst, New South Wales 2010, Australia
  • St George Hospital /ID# 154954
    Kogarah, New South Wales 2217, Australia
  • Liverpool Hospital /ID# 222410
    Liverpool, New South Wales 2170, Australia
  • Calvary Mater Newcastle /ID# 154957
    Waratah, New South Wales 2298, Australia
  • Duplicate_Princess Alexandra Hospital /ID# 154990
    Woolloongabba, Queensland 4102, Australia
  • Austin Health /ID# 154955
    Heidelberg, Victoria 3084, Australia
  • The Alfred Hospital /ID# 154956
    Melbourne, Victoria 3004, Australia
  • Fiona Stanley Hospital /ID# 222847
    Murdoch, Western Australia 6150, Australia
  • Juravinski Cancer Centre /ID# 152947
    Hamilton, Ontario L8V 1C3, Canada
  • Centre Hospitalier Universitaire de Nantes, Hotel Dieu -HME /ID# 153828
    Nantes, Pays de la Loire Region 44000, France
  • Hôpital Saint-Louis /ID# 153827
    Paris, 75010, France
  • Universitatsklinikum Mannheim /ID# 153140
    Mannheim, Baden-Wurttemberg 68167, Germany
  • Klinikum rechts der Isar /ID# 153139
    Munich, Bavaria 81675, Germany
  • Universitaetsklinikum Koeln /ID# 153141
    Cologne, North Rhine-Westphalia 50937, Germany
  • Duplicate_Universitaetsklinikum Carl Gus /ID# 153958
    Dresden, Saxony 01307, Germany
  • Universitaetsklinikum Leipzig /ID# 153142
    Leipzig, Saxony 04103, Germany
  • Universitaetsklinikum Halle (Saale) /ID# 153760
    Halle, 06120, Germany
  • Duplicate_IRCCS AOU di Bologna - Policlinico Sant'Orsola-Malpighi /ID# 153763
    Bologna, Emilia-Romagna 40138, Italy
  • Duplicate_Azienda Ospedaliero-Universitaria Policlinico Umberto I /ID# 153764
    Rome, Roma 00161, Italy
  • Norfolk and Norwich University Hospitals NHS Foundation Trust /ID# 156492
    Norwich, Norfolk NR4 7UY, United Kingdom
  • Oxford University Hospitals NHS Foundation Trust /ID# 222567
    Oxford, Oxfordshire OX3 9DU, United Kingdom
  • University Hospitals Birmingham NHS Foundation Trust /ID# 158810
    Birmingham, B15 2TH, United Kingdom
  • King's College Hospital NHS Foundation Trust /ID# 156489
    London, SE5 9RS, United Kingdom
08

References and documents

Publications

  • Garcia JS, Platzbecker U, Odenike O, Fleming S, Fong CY, Borate U, Jacoby MA, Nowak D, Baer MR, Peterlin P, Chyla B, Wang H, Ku G, Hoffman D, Potluri J, Garcia-Manero G. Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes. Blood. 2025 Mar 13;145(11):1126-1135. doi: 10.1182/blood.2024025464. PubMed 39652823 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Apr 2026, 111 months.

Of 84 industry-sponsored phase 1 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 72. This study's 111 months is above that.

Counting every sponsor, half of 220 studies reached it within 52 months; a quarter within 31 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2016
First posted
Oct 24, 2016
StartActual
Jan 12, 2017
Primary completionActual
Apr 15, 2026
CompletionActual
Apr 15, 2026
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02942290
Lead sponsor
AbbVie
Collaborators
Genentech, Inc.
Responsible party
Sponsor
First posted
Oct 24, 2016
Start date
Jan 12, 2017
Primary completion
Apr 15, 2026
Completion
Apr 15, 2026
Last update
Aug 12, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Azacitidine · Venetoclax

Start the discussion